6-chloro-N-methyl-7-aza-indole-2-boronic acid | 1255871-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 6-chloro-N-methyl-7-aza-indole-2-boronic acid
• 英文别名: 6-chloro-N-methyl-7-aza indole-2-boronic acid；(6-chloro-1-methylpyrrolo[2,3-b]pyridin-2-yl)boronic acid
• CAS: 1255871-24-9
• 化学式: C₈H₈BClN₂O₂
• 分子量: 210.428
• InChiKey: XIWHDFPFBIOJDI-UHFFFAOYSA-N

物化性质

• 沸点：
  446.0±55.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.09
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-chloro-N-methyl-7-aza-indole-2-boronic acid 在 titanium(IV) isopropylate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects

  摘要：

  Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in predinical species and human subjects of the selective CYP11B2 inhibitor 8.

  DOI：

  10.1021/acs.jmedchem.5b01545
• 作为产物：
  描述：

  6-氯-7-氮杂吲哚 在 叔丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 、 正戊烷 为溶剂， 反应 4.33h， 生成 6-chloro-N-methyl-7-aza-indole-2-boronic acid
  参考文献：
  名称：

  [EN] ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS
  [FR] ARYLPYRIDINE EN TANT QU'INHIBITEURS DE L'ALDOSTÉRONE SYNTHASE

  摘要：

  本发明提供了一种式（I）的化合物；一种用于制造本发明化合物的方法，以及其治疗用途。本发明还提供了一种药理活性剂的组合和药物组成。

  公开号：

  WO2010130796A1

文献信息

• [EN] ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS<br/>[FR] ARYLPYRIDINE EN TANT QU'INHIBITEURS DE L'ALDOSTÉRONE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2010130796A1

  公开（公告）日：2010-11-18

  The present invention provides a compound of Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种式（I）的化合物；一种用于制造本发明化合物的方法，以及其治疗用途。本发明还提供了一种药理活性剂的组合和药物组成。
• ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS
  申请人：Chamoin Sylvie

  公开号：US20130035354A1

  公开（公告）日：2013-02-07

  The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供一种I式化合物；一种制造本发明化合物的方法以及其治疗用途。本发明还提供一种药理活性剂的组合和一种制药组合物。
• Aryl pyridine as aldosterone synthase inhibitors
  申请人：Chamoin Sylvie

  公开号：US08383827B2

  公开（公告）日：2013-02-26

  The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种I式化合物；一种制造本发明化合物的方法，以及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• Discovery of <i>N</i>-[5-(6-Chloro-3-cyano-1-methyl-1<i>H</i>-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects
  作者：Julien P. N. Papillon、Changgang Lou、Alok K. Singh、Christopher M. Adams、Gary M. Ksander、Michael E. Beil、Wei Chen、Jennifer Leung-Chu、Fumin Fu、Lu Gan、Chii-Whei Hu、Arco Y. Jeng、Daniel LaSala、Guiqing Liang、Dean F. Rigel、Kerry S. Russell、John A. Vest、Catherine Watson

  DOI：10.1021/acs.jmedchem.5b01545

  日期：2015.12.10

  Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in predinical species and human subjects of the selective CYP11B2 inhibitor 8.